Publish in OALib Journal

ISSN: 2333-9721

APC: Only $99


Any time

2019 ( 134 )

2018 ( 514 )

2017 ( 569 )

2016 ( 599 )

Custom range...

Search Results: 1 - 10 of 26045 matches for " anti-diabetes therapy "
All listed articles are free for downloading (OA Articles)
Page 1 /26045
Display every page Item
Harnessing the potential clinical use of medicinal plants as anti-diabetic agents
Campbell-Tofte JI, M lgaard P, Winther K
Botanics: Targets and Therapy , 2012, DOI: http://dx.doi.org/10.2147/BTAT.S17302
Abstract: rnessing the potential clinical use of medicinal plants as anti-diabetic agents Review (1726) Total Article Views Authors: Campbell-Tofte JI, M lgaard P, Winther K Published Date August 2012 Volume 2012:2 Pages 7 - 19 DOI: http://dx.doi.org/10.2147/BTAT.S17302 Received: 24 January 2012 Accepted: 23 April 2012 Published: 22 August 2012 Joan IA Campbell-Tofte,1 Per M lgaard,2 Kaj Winther1 1Department of Clinical Biochemistry, Frederiksberg University Hospital, Frederiksberg, Denmark; 2Department of Medicinal Chemistry, Faculty of Pharmaceutical Sciences, University of Copenhagen, Copenhagen, Denmark Abstract: Diabetes is a metabolic disorder arising from complex interactions between multiple genetic and/or environmental factors. The characteristic high blood sugar levels result from either lack of the hormone insulin (type 1 diabetes, T1D), or because body tissues do not respond to the hormone (type 2 diabetes, T2D). T1D patients currently need exogenous insulin for life, while for T2D patients who do not respond to diet and exercise regimes, oral anti-diabetic drugs (OADs) and sometimes insulin are administered to help keep their blood glucose as normal as possible. As neither the administration of insulin nor OADs is curative, many patients develop tissue degenerative processes that result in life-threatening diabetes comorbidities. Several surveys of medicinal plants used as anti-diabetic agents amongst different peoples have been published. Some of this interest is driven by the ongoing diabetes pandemic coupled with the inadequacies associated with the current state of-the-art care and management of the syndrome. However, there is a huge cleft between traditional medicine and modern (Western) medicine, with the latter understandably demanding meaningful and scientific validation of anecdotal evidence for acceptance of the former. The main problems for clinical evaluation of medicinal plants with promising anti-diabetic properties reside both with the complexity of components of the plant materials and with the lack of full understanding of the diabetes disease etiology. This review is therefore focused on why research activities involving an integration of Systems Biology-based technologies of pharmacogenomics, metabolomics, and bioinformatics with standard clinical data, should be used for cost-effective validation of the safety and anti-diabetic efficacy of promising medicinal plants. The application of such approaches to studying entire mixtures of plant materials will ensure proper elucidation of novel therapies with improved mechanisms of action, as well as facilitate a personalized clinical use of medicinal plants as anti-diabetic agents.
Anti-diabetes activity of ethanol extract of Centella asiatica (L.) Urban (whole plant) in Streptozotocin-induced diabetic rats, isolation of an active fraction and toxicity evaluation of the extract
International Journal of Medicinal and Aromatic Plants , 2011,
Abstract: The study was carried out to evaluate the anti-diabetes activity of ethanol extract of Centella asiatica (L.) Urban in streptozotocin diabetic rats, to determine the acute and subacute toxicity of the extract in mice and to isolate most active anti-hyperglyceamic fraction of ethanol extract. Diabetes was induced in male Wistar rats by streptozotocin (50mg/kg) injection and anti-diabetes efficacy of various doses of ethanol extract was tested. Among the various doses tested, ethanol extract at a dose of 200 mg/kg showed significant anti-diabetes activity in streptozotocin diabetic rats as judged from body weight, serum glucose, lipids, cholesterol and urea, and liver glycogen levels. However, the extract did not significantly influence the levels of serum insulin in both diabetic and normoglycemic rats. In acute and sub-acute toxicity evaluation of the ethanol extract in all tested doses did not showed any conspicuous toxicity in mice. The active ethanol extract was suspended in water and sequentially fractionated with petroleum ether, chloroform, ethyl acetate and butanol and their anti-hyperglyceamic activity was determined in glucose loaded normal rats by glucose tolerance test. Among the fractions tested, anti-hyperglycemic activity was found predominantly in the chloroform fraction (12.5mg/kg) of alcohol extract. The active chloroform fraction when subjected to qualitative chemical analysis showed positive test to the presence of terpenoids, coumarins and saponins. Thus ethanol extract and its chloroform fraction of C. asiatica (L.) Urban open up a new vista for the discovery of new generations single or combinational safe oral hypoglycemic agents.
Antihyperglycemic activity of agarwood leaf extracts in STZ-induced diabetic rats and glucose uptake enhancement activity in rat adipocytes
Ratree Pranakhon,Patchareewan Pannangpetch,Chantana Aromdee
Songklanakarin Journal of Science and Technology , 2011,
Abstract: Agarwood leaf extract was found to possess antipyretic, laxative and antimicrobial activities. A trial of one diabeticpatient taking long term agarwood leaf tea was found to have blood glucose returned to normal. In this work, the effects ofmethanol, water and hexane crude extracts of agarwood leaf on hyperglycemia in streptozotocin-induced diabetic rats wereinvestigated. Only methanol and water extracts at the dose of 1 g/kg body weight lowered the fasting blood glucose levels,54 and 40%, respectively. The results were comparable to 4 U/kg body weight of insulin (73%). In in vitro experiment, theeffect of the methanol and water extracts at the concentration of 10 g/mL enhanced glucose uptake activity on ratadipocytes by 172±10 and 176±21% of the control, respectively. The glucose uptake enhancement activity is comparable to1.5 nM insulin (166±16%). The thin-layer chromatographic characteristics of all extracts were documented. The findingssuggest that agarwood leaf is a promising potential antidiabetic agent.
HPN, a Synthetic Analogue of Bromophenol from Red Alga Rhodomela confervoides: Synthesis and Anti-Diabetic Effects in C57BL/KsJ-db/db Mice
Dayong Shi,Shuju Guo,Bo Jiang,Chao Guo,Tao Wang,Luyong Zhang,Jingya Li
Marine Drugs , 2013, DOI: 10.3390/md11020350
Abstract: 3,4-Dibromo-5-(2-bromo-3,4-dihydroxy-6-(isopropoxymethyl)benzyl)benzene-1,2-diol (HPN) is a synthetic analogue of 3,4-dibromo-5-(2-bromo-3,4-dihydroxy-6-(ethoxymethyl)benzyl)benzene-1,2-diol (BPN), which is isolated from marine red alga Rhodomela confervoides with potent protein tyrosine phosphatase 1B (PTP1B) inhibition (IC 50 = 0.84 μmol/L). The in vitro assay showed that HPN exhibited enhanced inhibitory activity against PTP1B with IC 50 0.63 μmol/L and high selectivity against other PTPs (T cell protein tyrosine phosphatase (TCPTP), leucocyte antigen-related tyrosine phosphatase (LAR), Src homology 2-containing protein tyrosine phosphatase-1 (SHP-1) and SHP-2). The results of antihyperglycemic activity using db/ db mouse model demonstrated that HPN significantly decreased plasma glucose ( P < 0.01) after eight weeks treatment period. HPN lowered serum triglycerides and total cholesterol concentration in a dose-dependent manner. Besides, both of the high and medium dose groups of HPN remarkably decreased HbA1c levels ( P < 0.05). HPN in the high dose group markedly lowered the insulin level compared to the model group ( P < 0.05), whereas the effects were less potent than the positive drug rosiglitazone. Western blotting results showed that HPN decreased PTP1B levels in pancreatic tissue. Last but not least, the results of an intraperitoneal glucose tolerance test in Sprague–Dawley rats indicate that HPN have a similar antihyperglycemic activity as rosiglitazone. HPN therefore have potential for development as treatments for Type 2 diabetes.
- , 2018,
Abstract: 为了得到持续稳定控制血糖的胰高血糖素样肽-1(glucagon-like peptide-1,GLP-1)类似物,将平均相对分子质量为350、550和750的单甲氧基聚乙二醇(mPEG)分别缀合到GLP-1肽链上,设计并合成了12个衍生物。初步药理活性表明,所得化合物均保留GLP-1受体激动活性,其中化合物I-12降糖活性维持时间与艾塞那肽(Ex-4)和利拉鲁肽(Liraglutide)相当,具备成为新型长效化GLP-1受体激动剂的潜力。
In order to obtain glucagon-like peptide-1(GLP-1)analogs which can sustainedly control the levels of glucose, 12 derivatives were designed and synthesized by coupling monomethoxy polyethylene glycol(mPEG, with average molecular weights of 350, 550 and 750)to GLP-1 analogs. Preliminary pharmacological activities showed that all compounds retained GLP-1 receptor agonist activities, and the hypoglycemic activity of compound I-12 was similar to those of Ex-4 and Liraglutide, suggesting I-12 could be a potential long-acting GLP-1 receptor agonist
Disease Prevention and Alleviation by Human Myoblast Transplantation  [PDF]
Peter K. Law
Open Journal of Regenerative Medicine (OJRM) , 2016, DOI: 10.4236/ojrm.2016.52003
Abstract: Myoblast implantation is a unique, patented technology of muscle regeneration being tested in Phase III clinical trials of muscular dystrophy, ischemic cardiomyopathy, Phase II trial of cancer, and Phase I trial of Type II diabetes. Differentiated and committed, myoblasts are not stem cells. Implanted myoblasts fuse spontaneously among themselves, replenishing genetically normal myofibers. They also fuse with genetically abnormal myofibers of muscular dystrophy, cardiomyopathy, or Type II diabetes, transferring their nuclei containing the normal human genome to provide stable, long-term expression of the missing gene products. They develop to become cardiomyocytes in the infracted myocardium. Myoblasts transduced with VEGF165 allow concomitant regeneration of blood capillaries and myofibers. They are potent biologics for treating heart failure, ischemic cardiomyopathy, diabetic ischemia, erectile dysfunction, and baldness. Myoblasts, because of their small size, spindle shape, and resilience, can grow within wrinkles and on skin surfaces, thus enhancing the color, luster and texture of the skin “plated” with them. They can be injected subcutaneously as a cellular filler to reduce wrinkles. Intramuscular injection of myoblasts can augment the size, shape, consistency, tone and strength of muscle groups, improving the lines, contours and vitality to sculpt a youthful appearance. This highly promising technology has great social economic values in treating hereditary, fatal and debilitating disease conditions.
Therapeutic angiomyogenesis using human non-viral transduced VEGF165-myoblasts  [PDF]
Peter K. Law, Lei Ye, Husnain Kh. Haider, Ping Lu, Danlin M. Law, Eugene K. W. Sim
Open Journal of Regenerative Medicine (OJRM) , 2012, DOI: 10.4236/ojrm.2012.11001
Abstract: This article reviews the scientific development of angiomyogenesis using VEGF165-myoblasts, a patented biotechnology platform in regenerative medicine associated with Human Myoblast Genome Therapy (HMGT), also known as Myoblast Transfer Therapy (MTT). VEGF165-myoblasts are the leading biologics for angiomyogenesis. This review also compares the safety and efficacy of VEGF165-myoblasts transduced using adenoviral vectors, nanoparticles or liposomes, in anticipation of their application in clinical trials in the near future. VEGF165-myoblasts are differentiated myogenic cells capable of extensive division, natural cell fusion, nucleus transfer, cell therapy and genome therapy. Following transplantation they survive, develop and function to revitalize degenerative myocardium in heart failure and ischemic cardiomyopathy animal studies. VEGF165-myoblasts are second generation products of HMGT/MTT which replenishes live cells and genetically repairs degenerating myofibers in Type II diabetes, muscular dystrophies, aging dysfunction and disfigurement. Myoblasts have also been used to enhance skin and muscle appearance in cosmetology. We envision that VEGF165-myoblasts will provide better outcome than their non-tranduced counterparts. Myoblasts are not stem cells. Their competitive advantages over stem cells are presented.
Concerns about Diabetic Foot Wounds  [PDF]
Denis E. Solomon
Open Journal of Regenerative Medicine (OJRM) , 2019, DOI: 10.4236/ojrm.2019.81001
Abstract: This paper in a medical sense can be described as a case report. The diabetic foot wounds of a relative, over 70 years of age, with Type I diabetes were so grievous and the medical treatment was so protracted that success could not be assured. There was a danger of amputation. The one outstanding feature was that the private application of an antifungal spray, between the toes of both feet without prescribed oral mycologic agents, seemed to make an inexplicable difference to the final outcome. In addition, a viewpoint drawn was that the efficacy of antibiotic therapies may be compromised by the presence of invisible fungal etiology.
Therapeutic Modalities in Diabetic Nephropathy: Future Approaches  [PDF]
William Brian Reeves, Bishal B. Rawal, Emaad M. Abdel-Rahman, Alaa S. Awad
Open Journal of Nephrology (OJNeph) , 2012, DOI: 10.4236/ojneph.2012.22002
Abstract: Diabetes mellitus is the leading cause of end stage renal disease and is responsible for more than 40% of all cases in the United States. Several therapeutic interventions for the treatment of diabetic nephropathy have been developed and implemented over the past few decades with some degree of success. However, the renal protection provided by these therapeutic modalities is incomplete. More effective approaches are therefore urgently needed. Recently, several novel therapeutic strategies have been explored in treating DN patients including Islet cell transplant, Aldose reductase inhibitors, Sulodexide (GAC), Protein Kinase C (PKC) inhibitors, Connective tissue growth factor (CTGF) inhibitors, Transforming growth factor-beta (TGF-β) inhibitors and bardoxolone. The benefits and risks of these agents are still under investigation. This review aims to summarize the utility of these novel therapeutic approaches.
Role of Anti Angiogenic Therapy in Prevention of Recurrence in Hormonal Positive Breast Cancer: A Secondary Prevention Strategy and Method of Therapy  [PDF]
M. A. Nezami, Jessica Garner
Journal of Cancer Therapy (JCT) , 2017, DOI: 10.4236/jct.2017.86046
Abstract: Existing literature supports the role of signaling protein vascular endothelial growth factor (VEGF) in tumor growth and metastasis and furthers its involvement in recurrence. In both experimental and clinical studies, VEGF has been shown to be a significant factor involved for aberrant blood vessel growth, and in fact is the target of several classes of antineoplastic drugs [1] [2] [3] [4]. That said, the current standard of care for estrogen receptor positive breast cancer (although improved over the last decade), has not provided a “meaningful preventive shift” since the discovery of angiogenesis and its role in induction of recurrence. In this article, we discuss an anti angiogenic therapy implementing natural compounds to inhibit the production of VEGF. We applied our preclinical data to justify the predicted effect on VEGF. We used liquid biopsy to monitor patients response to therapy as a surrogate for recurrence. We hypothesize that by inhibition of angiogenesis through this protocol, we are able to positively impact tumor recurrence. It is our experience that patients in our sample even with high recurrence scores (based on Oncotype Dx testing) had a major reduction in recurrence when estrogen blockers were combined with this protocol. We also propose longitudinal studies to compare outcomes with combinational therapies with estrogen blockers in highly expected to recur disease.
Page 1 /26045
Display every page Item

Copyright © 2008-2017 Open Access Library. All rights reserved.